The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?
Open accessAbstract
Radiotherapy is a cornerstone of both curative and palliative cancer care. However, radiotherapy is severely limited by radiation-induced toxicities. If these toxicities could be reduced, a greater dose of radiation could be given therefore facilitating a better tumor response. Initial pre-clinical studies have shown that irradiation at dose rates far exceeding those currently used in clinical contexts reduce radiation-induced toxicities whilst maintaining an equivalent tumor response. This is known as the FLASH effect. To date, a single patient has been subjected to FLASH radiotherapy for the treatment of subcutaneous T-cell lymphoma resulting in complete response and minimal toxicities. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy is yet to be elucidated, but the most prominent hypothesis so far proposed is that acute oxygen depletion occurs within the irradiated tissue. This review examines the tissue response to FLASH radiotherapy, critically evaluates the evidence supporting hypotheses surrounding the biological basis of the FLASH effect, and considers the potential for FLASH radiotherapy to be translated into clinical contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shaw, E., Scott, C., Souhami, L., Dinapoli, R., Kline, R., Loeffler, J., & Farnan, N. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00507-6 · Cited by 1,608
Favaudon, V., Caplier, L., Monceau, V., Pouzoulet, F., Sayarath, M., Fouillade, C., Poupon, M.-F., Brito, I., Hupé, P., Bourhis, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008973 · Cited by 1,476
Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia
Carreau, A., Hafny‐Rahbi, B. E., Matejuk, A., Grillon, C., & Kieda, C. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01258.x · Cited by 1,246
Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050
Widmark, A., Gunnlaugsson, A., Beckman, L., Thellenberg-Karlsson, C., Hoyer, M., Lagerlund, M., Kindblom, J., Ginman, C., Johansson, B., Björnlinger, K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31131-6 · Cited by 876
Montay-Gruel, P., Petersson, K., Jaccard, M., Boivin, G., Germond, J.-F., Petit, B., Doenlen, R., Favaudon, V., Bochud, F., Bailat, C., et al. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.05.003 · Cited by 692
Self-citationLong-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species
Montay-Gruel, P., Acharya, M. M., Petersson, K., Alikhani, L., Yakkala, C., Allen, B. D., Ollivier, J., Petit, B., Jorge, P. G., Syage, A. R., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901777116 · Cited by 599
Self-citationBiological Benefits of Ultra-high Dose Rate FLASH Radiotherapy: Sleeping Beauty Awoken
Vozenin, M.-C., Hendry, J. H., & Limoli, C. L. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.04.001 · Cited by 484
Clinical translation of FLASH radiotherapy: Why and how?
Bourhis, J., Montay-Gruel, P., Gonçalves Jorge, P., Bailat, C., Petit, B., Ollivier, J., Jeanneret-Sozzi, W., Ozsahin, M., Bochud, F., Moeckli, R., et al. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.04.008 · Cited by 474
Yovino, S., Kleinberg, L., Grossman, S. A., Narayanan, M., & Ford, E. (2013) · Cancer Investigation · doi:10.3109/07357907.2012.762780 · Cited by 417
Cited by
Towards clinical translation of FLASH radiotherapy
Vozenin, M.-C., Bourhis, J., & Durante, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00697-z · Cited by 363
FLASH Radiotherapy: Current Knowledge and Future Insights Using Proton-Beam Therapy
Hughes, J. R., & Parsons, J. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186492 · Cited by 267
MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40
Genome-wide determinants of mortality and motor progression in Parkinson’s disease
Tan, M. M. X., Lawton, M. A., Pollard, M. I., Brown, E., Real, R., Carrasco, A. M., Bekadar, S., Jabbari, E., Reynolds, R. H., Iwaki, H., et al. (2024) · npj Parkinson's Disease · doi:10.1038/s41531-024-00729-8 · Cited by 17
Metadata
- Authors
- Wilson, J. D., Hammond, E. M., Higgins, G. S., & Petersson, K.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-01-17
- Volume
- 9
- Pages
- 1563-1563
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2998202461
- Cited by
- 473
- References
- 38
- FWCI
- 38.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold? https://app.cochat.ai/papers/10.3389/fonc.2019.01563
- The paper
- Wilson, J. D., Hammond, E. M., Higgins, G. S., & Petersson, K. (2020). Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold? Frontiers in Oncology. https://doi.org/10.3389/fonc.2019.01563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
